Open AccessBasal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers
Author(s) -
Laura C. Collins,
Anthony Martyniak,
M. Kandel,
Zsofia K. Stadler,
Serena Masciari,
Alexander Miron,
Andrea L. Richardson,
Stuart J. Schnitt,
Judy E. Garber
Publication year - 2009
Publication title -
the american journal of surgical pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 210
eISSN - 1532-0979
pISSN - 0147-5185
DOI - 10.1097/pas.0b013e31819c1c93
Subject(s) - progesterone receptor , triple negative breast cancer , tissue microarray , breast cancer , epidermal growth factor receptor , cytokeratin , biology , estrogen receptor , basal (medicine) , germline mutation , cancer research , pathology , cancer , medicine , immunohistochemistry , mutation , endocrinology , immunology , genetics , gene , insulin
Over 80% of breast cancers in women with germline BRCA1 mutations are estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative ("triple negative") and most of these have a basal-like phenotype by expression profiling and immunophenotypic analysis. However, whether or not expression of biomarkers characteristic of basal-like breast cancers helps to define a subset of women with triple-negative breast cancers who are likely to harbor BRCA1 mutations is an unresolved issue.